NCT05672979View on ClinicalTrials.gov

Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy

PHASE3UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Age-Related Macular DegenerationPachychoroid Neovasculopathy
Interventions
DRUG

Brolucizumab Injection [Beovu]

brolucizumab 6mg intravitreal injection

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Yeungnam University College of Medicine

OTHER